Pharvaris (PHVS) Stock Price, News & Analysis

Company Overview

Pharvaris N.V. (NASDAQ: PHVS) is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder that causes recurrent episodes of swelling. The company was founded in 2015 by individuals with experience in HAE drug development and aims to provide convenient, non-injectable treatment options for patients.

Pharvaris’ lead investigational product is deucrictibant, an oral bradykinin B2 receptor antagonist designed for use both as an on-demand treatment for HAE attacks and as a preventive therapy. The company’s drug-development approach is intended to address the need for oral alternatives to currently available injectable or infused HAE treatments.

Pharvaris is headquartered in Zug, Switzerland, and conducts research and clinical-development activities internationally, including in North America and Europe. The company’s shares began trading on the Nasdaq Global Select Market in 2021. Pharvaris is led by Chief Executive Officer Berndt Modig, who has experience in the development and commercialization of medicines for rare diseases.

Key Stats

• Today's Range: $30.55 to $31.50
• 50-Day Range: $27.74 to $38.86
• 52-Week Range: $21.02 to $43.25
• Volume: 393,548 shs
• Average Volume: 719,172 shs
• Market Capitalization: $2.01 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $58.60
• Consensus Rating: Moderate Buy

Pharvaris Stock Analysis - MarketRank™

Pharvaris scored higher than 70% of companies evaluated by MarketBeat, and ranked 209th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Pharvaris has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 13 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Pharvaris has a consensus price target of $58.60, representing about 91.1% upside from its current price of $30.66.

Amount of Analyst Coverage

Pharvaris has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Pharvaris are expected to grow in the coming year, from ($3.12) to ($3.01) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pharvaris is -10.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pharvaris is -10.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pharvaris has a P/B Ratio of 6.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.48% of the float of Pharvaris has been sold short.

Short Interest Ratio / Days to Cover

Pharvaris has a short interest ratio ("days to cover") of 2.84, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pharvaris has recently increased by 12.51%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pharvaris does not currently pay a dividend.

Dividend Growth

Pharvaris does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: N/A

News Sentiment

Pharvaris has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Pharvaris this week, compared to 5 articles on an average week.

Search Interest

Only 5 people have searched for PHVS on MarketBeat in the last 30 days. This is a decrease of -62% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added Pharvaris to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Pharvaris insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $18,643,666.00 in company stock.

Percentage Held by Insiders

11.84% of the stock of Pharvaris is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Pharvaris has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/22/2026
• 3rd Annual Guggenheim Healthcare Innovation Conference: 11/09/2026
• Next Earnings (Estimated): 11/11/2026
• 9th Annual Evercore ISI HealthCONx Conference: 12/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PHVS
• CIK: 1830487
• Web: www.pharvaris.com
• Phone: 31-71-203-6410
• Fax: N/A
• Employees: 148
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Pharvaris: $58.60
• High Price Target: $79.00
• Low Price Target: $30.00
• Potential Upside/Downside: +91.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$198.79 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -61.40%
• Return on Assets: -56.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.94
• Quick Ratio: 11.94

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.71 per share
• Price / Book: 6.51

Miscellaneous

• Outstanding Shares: 65,410,000
• Free Float: 57,664,000
• Market Cap: $2.01 billion
• Optionable: Optionable
• Beta: -2.46